Variant Summary
- Also known as
- A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM
- HGVS
- NC_000017.10:g.37880993_37880994insGCTTACGTGATG,NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT
- Variant Type(s)
- inframe_insertion
- Evidence Items
- 7
Evidence Level Distribution
Level A: 1Level B: 1Level C: 3Level D: 2
Evidence Items
Showing CIViC evidence rows where gene = ERBB2 and variant = Y772_A775DUP.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 4 |
| D | Predictive | Supports | Sensitivity/Response | Lung Carcinoma | Afatinib | 4 |
| A | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Trastuzumab Deruxtecan | 4 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Trastuzumab Emtansine | 3 |
| C | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Afatinib | 3 |
| D | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Afatinib,Sirolimus | 3 |
| B | Predictive | Does Not Support | Sensitivity/Response | Lung Non-small Cell Carcinoma | Dacomitinib | 2 |